Cargando…
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Lung cancer is the leading cause of cancer deaths, and effective treatments are urgently needed. Loss-of-function mutations in the DNA damage response kinase ATM are common in lung adenocarcinoma but directly targeting these with drugs remains challenging. Here we report that ATM loss-of-function is...
Autores principales: | Smida, Michal, Fece de la Cruz, Ferran, Kerzendorfer, Claudia, Uras, Iris Z., Mair, Barbara, Mazouzi, Abdelghani, Suchankova, Tereza, Konopka, Tomasz, Katz, Amanda M., Paz, Keren, Nagy-Bojarszky, Katalin, Muellner, Markus K., Bago-Horvath, Zsuzsanna, Haura, Eric B., Loizou, Joanna I., Nijman, Sebastian M. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5150652/ https://www.ncbi.nlm.nih.gov/pubmed/27922010 http://dx.doi.org/10.1038/ncomms13701 |
Ejemplares similares
-
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity
por: Mair, Barbara, et al.
Publicado: (2016) -
A chemical genetic screen reveals a resistance mechanism to PI3K inhibitors in cancer
por: Muellner, Markus K, et al.
Publicado: (2011) -
A thesaurus of genetic variation for interrogation of repetitive genomic regions
por: Kerzendorfer, Claudia, et al.
Publicado: (2015) -
TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens
por: Muellner, Markus K, et al.
Publicado: (2014) -
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
por: Pastorino, Lorenza, et al.
Publicado: (2022)